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ABSTRACT
In the United Kingdom (UK), both the MF59-adjuvanted quadrivalent influenza vaccine (aQIV) and the 
high-dose QIV (QIV-HD) are preferred for persons aged 65 years and older but only aQIV is reimbursed by 
the National Health Service (NHS). The objective was to determine the potential cost-effectiveness of 
vaccinating adults aged 65 years and above with aQIV compared with QIV-HD in the UK. A dynamic 
transmission model, calibrated to match infection data from the UK, was used to estimate the impact of 
vaccination in 10 influenza seasons. Vaccine effectiveness was based on a meta-analysis that concluded 
the vaccines were not significantly different. Vaccine coverage, physician visits, hospitalizations, deaths, 
utility losses and NHS costs were estimated using published UK sources. The list price of aQIV was £11.88 
while a range of prices were tested for QIV-HD. The price of the trivalent high-dose vaccine (TIV-HD) is 
£20.00 but a list price for QIV-HD is not yet available. The projected differences between the vaccines in 
terms of clinical cases and influenza treatment costs are minimal. Our analysis demonstrates that in order 
to be cost-effective, the price of QIV-HD must be similar to that of aQIV and may range from £7.57 to 
£12.94 depending on the relative effectiveness of the vaccines. The results of the analysis were most 
sensitive to variation in vaccine effectiveness and the rate of hospitalization due to influenza. Given the 
evidence, aQIV is cost-saving unless QIV-HD is priced lower than the existing list price of TIV-HD.
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In the United Kingdom (UK), seasonal influenza vaccines have 
been provided to those at high risk of complications as well as 
those aged 65 years and above since 2000.1 In 2013, a phased 
introduction to ages 2 to 16 years also began.2 Individuals aged 
65 years and above are at increased risk of complications and 
death from influenza compared with any other age group.3,4 In 
addition, these older adults have a lower immune response to 
vaccines than younger people5 and standard egg-based quad-
rivalent influenza vaccines have had poor effectiveness in this 
age group in the UK.6,7 The Joint Committee on Vaccination 
and Immunisation (JCVI) recommended the use of alternative 
influenza vaccines that have improved effectiveness in this age 
group as the preferred vaccines for the 2019/20 and 2020/21 
seasons.8,9 While this includes both the MF59 adjuvanted tri-
valent influenza vaccine (aTIV) and a high-dose trivalent influ-
enza vaccine (TIV-HD), only aTIV was reimbursed by the 
National Health Service (NHS) given the list price for TIV- 
HD.10
For the 2021/22 season, the JCVI has recommended the use 
of the new quadrivalent versions of these vaccines,11 although 
only the aQIV will currently be reimbursed by the NHS.12 Both 
the MF59 adjuvanted quadrivalent influenza vaccine (aQIV) 
and the high-dose quadrivalent influenza vaccine (QIV-HD) 
are considered to be the preferred vaccines for this older age 
group. The JCVI considers that the evidence comparing the 
two vaccines is limited, inconsistent and at-risk of bias.11 They 
require data from multiple seasons before they can determine if 
one of these vaccines has superior effectiveness and make 
a preferential recommendation for one over the other.
In this analysis, we explore and compare the clinical and 
economic impact of the use of each of the available enhanced 
vaccines. The specific objective is to determine the potential 
cost-effectiveness of vaccination of adults aged 65 years and 
above with aQIV compared with QIV-HD in the UK, using 
a range of pricing and relative effectiveness assumptions for 
QIV-HD.
Methods
In this analysis, we used a compartmental transmission model 
with a Susceptible-Exposed-Infectious-Recovered (SEIR) type 
structure to predict the number of influenza infections with 
and without vaccination. While the specific target population 
was individuals aged 65 years and older in the UK, the entire 
population was included as is typical for dynamic models of 
communicable diseases. This allowed the estimation of both 
the direct benefits achieved through vaccination of the specific 
target population and the indirect effects achieved through 
a reduction in transmission of the virus through the entire 
population. The approach to creating the transmission model 
was adopted from Baguelin and colleagues who have created 
models of independent influenza seasons in order to conduct 
cost-effectiveness analyses of vaccine policy changes for the 
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UK.13–17 Details on the transmission model structure and the 
calibration of the model inputs have been described earlier.18 
During calibration, we created a scenario where type 
A dominates and a second scenario where both types A and 
B are co-circulating.
Vaccine effectiveness
In those aged 65 years and older, we compared the use of aQIV 
and QIV-HD. The influenza vaccinations administered to the 
other age groups were held constant for all model runs: the cost 
and effectiveness of these vaccines are described in Supplemental 
Appendix #1. The relative vaccine effectiveness of aTIV com-
pared with TIV-HD has been estimated in several observational 
cohort studies.19–25 Coleman et al. conducted a systematic litera-
ture review and meta-analysis of studies with aTIV, including 
those comparing aTIV with TIV-HD.26 Using data from four 
studies,19,20,24,25 they estimated that the relative vaccine effective-
ness (rVE) of aTIV to TIV-HD for reducing any medical encoun-
ter due to influenza and/or pneumonia was 3.2%. The 95% 
confidence interval for the rVE ranged from −2.5% to 8.9%, 
indicating that there was no statistically significant difference in 
the effectiveness of the two vaccines. The relative vaccine effec-
tiveness is defined as one minus the rate ratio of the two vaccines. 
The rate ratio is defined as the ratio of the incidence rates of the 
two vaccines.19 In randomized controlled trials, the immune 
response in those given aQIV and QIV-HD was shown to be 
non-inferior to those receiving aTIV and TIV-HD respectively 
for homologous influenza strains and superior for the additional 
B strain.27–29 For this analysis, we therefore assumed that the rVE 
of aQIV compared with QIV-HD is the same as the rVE of aTIV 
compared with TIV-HD. For the base case analysis, we created 
three effectiveness scenarios using the Coleman meta-analysis: 
the values for the rVE of aQIV compared with QIV-HD were set 
to −2.5%, 3.2% and 8.9% – corresponding to the point estimate 
from the meta-analysis and the ends of the confidence interval.
Time horizon
We conducted analyses across 10 different seasons, although 
results are presented as the average annual (i.e. per season) values. 
We used 2019 data for the size of the population in Year 1 and 
applied the average growth rate from the Office for National 
Statistics for each year thereafter.30 The type of influenza infection 
across the 10 years varied according to data from the Public 
Health England (PHE) surveillance reports from the 2010/11 to 
2019/20 seasons.31–40 Consistent with these data, we assumed that 
an A&B season occurred for Years 1, 3, and 8 while A only was 
experienced in the other seasons. We also varied the proportion of 
A infections due to H1N1 and H3N2 infections to match the PHE 
data (See Supplemental Appendix #1). We acknowledge that 
10 years of data is a small sample on which to base future projec-
tions, but unfortunately longer-term data are not available.
Vaccine coverage
We stratified all compartments in the transmission model into 
those at low and high risk (called at-risk) of complications 
from influenza. The proportion at-risk of complications in 
each age group came from presented in previously published 
UK analyses (Table 1).14–16 Since 2004/05, vaccine coverage for 
those aged 65 years and above has varied between 70.5% to 
75.3%.1 For the base case, we sourced vaccine coverage for each 
age group from the previous UK analysis (Table 1).17 We 
assumed that vaccine coverage was independent of the specific 
vaccination used and therefore used the same coverage level for 
aQIV and QIV-HD.
Treatment of clinical influenza
Each case of symptomatic (or clinical) influenza predicted by 
the transmission model enters a decision tree, which calculates 
the proportion of cases that receive outpatient or inpatient 
treatment or both. Only individuals treated in hospital faced 
a probability of dying from influenza. Similar to previous 
analyses, we assumed that 10% of clinical infections receive 
outpatient care for their infections.13,41 We used calibration to 
derive the probability of hospitalization (Table 1) given infec-
tion so that the average rate of hospital admissions matched the 
overall rate of influenza admissions by age and risk group in 
a published analysis of the Hospital Episode Statistics 
database.3 Case fatality rates (Table 1) were based on the 30- 
day mortality rates in this study.3
Cost and utility inputs
We used the perspective of the NHS and Personal Social 
Services for costs, as recommended by the National Institute 
for Health and Care Excellence (NICE).42 The list price for 
aQIV is £11.88.43 As a list price for QIV-HD is not yet avail-
able, the unit price of QIV-HD was varied over a range of 
values up to a maximum of £20.00 which is the list price for 
TIV-HD.43 While the NHS is charged a 20% Value Added Tax 
(VAT) on vaccines, we did not include it in the analysis as it is 
considered a social transfer. Furthermore, we assumed that the 
cost of administration was the same regardless of the type of 
vaccine used.
The costs of outpatient and inpatient treatment were 
obtained from Pitman and colleagues,44 and inflated to 2020 
values.45 These outpatient costs, presented in Table 1, included 
both consultations and broad-spectrum antibiotics associated 
with complications such as acute otitis media, pneumonia, and 
sinusitis. We also added the cost of recommended anti-viral 
treatment for high-risk individuals46 to a portion of cases47 
using the British National Formulary costs.48 The age-specific 
hospitalization costs in Table 1 were derived by Pitman et al. 
from NHS reference costs for admissions for lobar, atypical or 
viral pneumonia without complications.
We assigned a disutility of 0.007515,49 to uncomplicated 
cases of influenza and 0.018015,50 to hospitalized cases of influ-
enza. We calculated quality-adjusted life-year (QALY) decre-
ments for nonfatal influenza cases by multiplying the disutility 
by the time spent in the corresponding health state. We calcu-
lated the discounted number of QALYs lost due to death from 
influenza using expected survival51 and expected age-specific 
utility values.52
We applied a discount rate of 3.5% for both costs and out-
comes in line with NICE recommendations.42
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Sensitivity analyses
We performed a pricing analysis to determine an economically 
justifiable price for QIV-HD for the different effectiveness 
scenarios assuming various thresholds for an acceptable cost 
per QALY. We ran several additional scenarios to test the 
sensitivity to variables other than vaccine effectiveness. First, 
in order to simulate the impact of more or less severe influenza 
seasons, we doubled and then halved the hospitalization rates. 
Second, we varied the QALY decrements using their 95% 
confidence intervals: 0.0002 to 0.0271 for uncomplicated dis-
ease and 0.0145 to 0.0217 for hospitalizations. Third, we 
increased and decreased the baseline utility values by 10% in 
order to vary the QALY loss associated with early death due to 
influenza. Finally, based on a recent methods review in which 
NICE acknowledged that ‘the evidence suggests there is a case 
to change the reference discount rate to 1.5% per year for both 
costs and effects,’ we performed a scenario analysis using this 
rate for both costs and outcomes.53
Results
In the base case analysis, there is a small difference favoring 
aQIV when the rVE of aQIV versus QIV-HD is 3.2% and 8.9% 
or favoring QIV-HD when rVE is −2.5%. The difference in the 
number of predicted clinical influenza cases in the UK popula-
tion is less than 2% for all scenarios (Table 2) while the 
difference in hospitalizations is 3% or less for all scenarios. 
The change in the average annual discounted NHS treatment 
costs for influenza range from a decrease of 1% to an increase 
of less than 4% (Table 2). As most deaths due to influenza 
occur in those age 65 years and older, vaccinating these indi-
viduals with a more effective vaccine has a slightly greater 
impact on the overall number of deaths in the population. If 
aQIV has a rVE of 8.9% compared with QIV-HD, then the use 
of QIV-HD in place of aQIV would lead to approximately 6% 
more deaths. Changes in number of deaths due to influenza 
impacts the QALYs lost predicted with influenza more than the 
changes in the loss of QALYs due to symptoms of influenza 
(Table 2). However, the absolute value of the change in average 
annual discounted QALYs when QIV-HD is implemented in 
place of aQIV is expected to be less than 1% in all scenarios.
The incremental cost-effectiveness ratio (ICER) of QIV-HD 
compared with aQIV is shown in Figure 1 for the three effec-
tiveness scenarios, for a range of unit prices for QIV-HD. In 
order for the ICER to fall below a cost per QALY willingness-to 
-pay threshold of £20,000, the unit price of QIV-HD needs to 
be less than £12.94 if the rVE is −2.5%, less than £10.44 if the 
rVE is 3.2% and less than £7.67 if the rVE is 8.9%.
The impact of the scenario analyses on the potential price of 
QIV-HD is shown in Figure 2. For all effectiveness scenarios, 
the economically justifiable unit cost of QIV-HD is affected 
most by changes in the hospitalization rates, followed by 
changes in the QALY decrements associated with influenza, 
followed by the changes in the baseline utility. The discount 
rate has a minimal impact. For example, for the rVE of aQIV 
versus QIV-HD of 3.2%, the price of QIV-HD should be below 
the aQIV price of £11.88 given the extra effectiveness regardless 
of the scenario. At a £20,000 willingness-to-pay threshold, the 
economically justifiable price of QIV-HD varies between £9.21 
with the high hospitalization rate to £11.05 with the low hos-
pitalization rate. In other words, the small increase in vaccine 
Table 1. Key inputs for the base case analysis.
Age group
6–23 months 2–6 years 7–17 years 18–49 years 50–59 years 60–64 years 65–74 years 75 years and above
Population at high risk of complication if infecteda,b,c
Proportion 4.90% 7.30% 9.60% 9.10% 18.30% 18.30% 45.00% 45.00%
Vaccine coveraged
Low Risk 0.10% 28.10% 27.60% 0.00% 0.00% 0.00% 68.00% 80.00%
High Risk 3.10% 48.60% 48.60% 48.60% 48.60% 48.60% 68.00% 80.00%
Probability of hospitalization given infectione
Low Risk 3.59% 2.72% 0.16% 0.19% 0.54% 0.60% 3.12% 3.15%
High Risk 3.16% 3.46% 1.03% 1.18% 3.25% 3.61% 5.69% 5.75%
Case fatality rate (per 1,000 hospitalized cases)e
Low risk 0.43 0.43 0.74 6.07 6.07 6.07 185.29 185.29
High risk 17.45 17.45 24.43 39.97 39.97 39.97 428.52 428.52
Cost of outpatient caref
Low Risk £94.35 £74.73 £76.24 £104.07 £124.51 £124.51 £125.35 £125.35
High Risk £98.36 £80.74 £84.25 £106.55 £126.99 £126.99 £125.35 £125.35
Cost of hospital admissionf
Average £1,985.33 £1,985.33 £2,006.59 £2,053.65 £2,451.38 £2,451.38 £6,618.61 £6,618.61
aThorrington D, van Leeuwen E, Ramsay M, Pebody R, Baguelin M. Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in England. BMC Med 2017; 
15:166. 
bBaguelin M, Camacho A, Flasche S, Edmunds WJ. Extending the elderly- and risk-group programme of vaccination against seasonal influenza in England and Wales: 
a cost-effectiveness study. BMC Med 2015; 13:236. 
cBaguelin M, Flasche S, Camacho A, Demiris N, Miller E, Edmunds WJ. Assessing optimal target populations for influenza vaccination programmes: an evidence synthesis 
and modeling study. PLoS Med 2013; 10:e1001527. 
dThorrington D, van Leeuwen E, Ramsay M, Pebody R, Baguelin M. Assessing optimal use of the standard dose adjuvanted trivalent seasonal influenza vaccine in the 
elderly. Vaccine 2019; 37:2051–6. 
eCromer D, van Hoek AJ, Jit M, Edmunds WJ, Fleming D, Miller E. The burden of influenza in England by age and clinical risk group: a statistical analysis to inform vaccine 
policy. J Infect 2014; 68:363–71. 
fPitman RJ, Nagy LD, Sculpher MJ. Cost-effectiveness of childhood influenza vaccination in England and Wales: Results from a dynamic transmission model. Vaccine 
2013; 31:927–42.
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effectiveness with aQIV in this scenario is worth more during 
a more severe influenza season than a less season influenza 
season. For this same analysis with rVE set to −2.5% (QIV-HD 
is more effective), the economically justifiable price of QIV-HD 
varied from £12.49 (fewer hospitalizations) to £13.84 (more 
hospitalizations). When the rVE was 8.9% (aQIV more effec-
tive), the economically justifiable price of QIV-HD varied from 
£3.90 (more hospitalizations) to £9.40 (fewer hospitalizations).
Discussion
We constructed three effectiveness scenarios using the results 
of a meta-analysis of the impact of aTIV and TIV-HD on the 
rate of medical encounters due to influenza and/or pneumonia. 
As the effectiveness of the vaccines was not statistically signifi-
cantly different, our projections of the implications of this 
result show that the differences between the vaccines in terms 
of clinical cases and influenza treatment costs are minimal. 
While the NHS list price for aQIV has been set to £11.88, the 
list price for QIV-HD is not yet available. Our analysis demon-
strates that in order to be cost-effective, the price of QIV-HD 
must be similar to that of aQIV and may range from £7.57 to 
£12.94 depending on the value assumed for rVE. The results 
are most sensitive to changes in the rate of hospitalization due 
to influenza and least sensitive to the discount rate. Typically, 
quadrivalent versions of vaccines cost more than the trivalent 
versions. Given that the latest list price of TIV-HD was £20.00, 
a considerable reduction in price would be required in order 
for QIV-HD to be considered cost-effective if effectiveness is 
similar to aQIV.
As with any decision analysis, there are several limitations 
associated with our analysis comparing aQIV and QIV-HD. 
Foremost is the lack of data on the relative effectiveness of the 
two vaccines. While there are some data comparing the trivalent 
versions of the vaccines, these are from observational analyses of 
large databases in the United States. As the JCVI states, additional 
effectiveness data are required from multiple seasons before they 
might recommend one vaccine as preferred to the other. The 
meta-analysis used in this cost-effectiveness study did summarize 
data from multiple seasons but found no significant differences 
between the trivalent versions of the vaccines. The quadrivalent 
formulations of these vaccines are new, but as they will both be 
available in upcoming seasons, comparative data will be available 
in the future from countries that have adopted both vaccines.
In this analysis, we estimated the number of influenza 
infections with a transmission model that has a number of 
limitations associated with the model structure and inputs. 
Similar to previously published influenza models,47,54,55 the 
model structure allowed the vaccine to reduce infection only 
and did not allow a differential response according to the 
severity of disease. Therefore, the same effectiveness was 
applied to reduction of transmission of disease, reduction in 
symptomatic disease and reduction in hospitalizations. The 
effectiveness data used were derived from the reduction of 
medical encounters including general practitioner visits, emer-
gency room visits and hospitalizations. Furthermore, we 
assumed a constant strain-specific effectiveness for all 
10 years but in reality, vaccine effectiveness varies each year 
depending on how well the strains chosen by the World Health 
Organization match the strains that circulate locally during the 
influenza season. Given this inherent variation in influenza 
vaccine effectiveness, we conducted our pricing analyses with 
several effectiveness scenarios to estimate the impact of varia-
tion on the estimated economically attractive price for QIV- 
HD.
One further limitation is the limited variability in influ-
enza infection rates in our model across the 10 seasons. While 
the burden of influenza varies by season, the model contains 
only two calibrated scenarios for an unvaccinated population: 
a representative A only and a representative A and 
B scenario. Our model does capture some additional varia-
tion in annual consequences of infection because vaccine 
effectiveness varies from season to season as the proportion 
of H1N1 and H3N2 circulating is varied. Overall, the model 
does not predict the same variability in outcomes across 
seasons that may be observed in the UK. PHE, for example, 
reports that the deaths in England attributed to influenza may 
vary from 4,000 to 22,000 annually,40 while the number of 
deaths predicted by the model varied only from approxi-
mately 2,000 to 4,000 each year. To counter this limitation, 
we conducted a set of analyses where we doubled and halved 
the hospitalization rate associated with our base case analyses. 
As all of the deaths associated with influenza in this model 
were assumed to occur in hospitalized individuals, this varied 
the mortality rate as well. Increasing the hospitalizations and 
deaths associated with influenza meant that a larger price 
differential could be justified between the less effective and 
the more effective vaccine if the willingness-to-pay for 
QALYs gained is held constant.
We chose the inputs for the economic portion of the model 
that calculated the costs and quality of life implications of this 
model to be consistent with past cost-effectiveness analyses 
Table 2. Base Case Results: Cases of clinical infection, hospitalizations, deaths, 
health-care system costs, and quality-adjusted life years with aQIV and QIV-HD 
under three relative effectiveness scenarios. All numbers, except for deaths from 
influenza, are presented rounded to the thousands.
Relative effectiveness (rVE) of aQIV 
versus QIV-HD rVE = −2.5% rVE = 3.2% rVE = 8.9%
Clinical Influenza Cases (thousands)
aQIV Strategy 2,616 2,615,577 2,615,577
QIV-HD Strategy 2,606 2,628,959 2,655,355
Percent Change -<1% 1% 2%
Hospitalizations (thousands)
aQIV Strategy 22 22 22
QIV-HD Strategy 22 22 23
Percent Change −0.8% 1% 3%
Deaths
aQIV Strategy 2,800 2,800 2,800
QIV-HD Strategy 2,800 2,900 3,000
Percent Change −2% 2% 6%
rVe = −2.5 rVE = 3.2 rVE = 8.9
Average annual discounted health-care system costs for influenza 
treatment* (thousands)
aQIV Strategy € 94,178 € 94,178 € 94,178
QIV-HD Strategy € 93,293 € 95,388 € 97,788
Percent Change −1% 1% 4%
Average discounted quality-adjusted life years per season of vaccination 
(thousands)
aQIV Strategy 51,414 51,414 51,414
QIV-HD Strategy 51,415 51,414 51,413
Percent Change <1% -<1% -<1%
* This cost includes influenza treatment costs but not the cost of vaccination.
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published for the UK.15,44 We conducted several scenario ana-
lyses where these were varied. While there are some limitations 
with these data, they appear to have a smaller impact on the 
cost-effectiveness results and the economically justifiable price 
of QIV-HD than vaccine effectiveness or severity of influenza. 
This is consistent with past analyses where vaccine effective-





Figure 1. The incremental cost-effectiveness of QIV-HD compared with aQIV over a range of unit prices for three relative effectiveness scenarios (rVE of aQIV versus QIV- 
HD): 8.9% (Panel A); 3.2% (Panel B); −2.5% (Panel C). A positive rVE implies that aQIV is more effective than QIV-HD while a negative rVE implies that QIV-HD is more 
effective than aQIV. aQIV – MF59 adjuvanted quadrivalent influenza vaccine; ICER – Incremental cost-effectiveness ratio; QALY – quality-adjusted life-years; QIV-HD – 
High dose quadrivalent inactivated influenza vaccine; rVE – relative vaccine effectiveness.




Figure 2. Scenario analyses: The incremental cost-effectiveness of QIV-HD compared with aQIV over a range of unit prices for three relative effectiveness scenarios (rVE 
of aQIV versus QIV-HD): 8.9% (Panel A); 3.2% (Panel B); −2.5% (Panel C). A positive rVE implies that aQIV is more effective than QIV-HD while a negative rVe implies that 
QIV-HD is more effective than aQIV. aQIV – MF59 adjuvanted quadrivalent influenza vaccine; CI – Confidence interval; ICER – Incremental cost-effectiveness ratio; QALY – 
quality-adjusted life-years; QIV-HD – High dose quadrivalent inactivated influenza vaccine; rVe – relative vaccine effectiveness.
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Conclusion
The current evidence of the rVE of aQIV and QIV-HD is not 
sufficient to suggest that either aQIV or QIV-HD is more 
effective. In this analysis, we used a range of rVE values from 
a recent meta-analysis that did not find a statistically significant 
difference in the effectiveness of the two vaccines to conduct 
a cost-effectiveness analysis for a range of unit prices for QIV- 
HD. Given the effectiveness evidence, aQIV is cost-saving com-
pared to QIV-HD priced at the existing list price of TIV-HD.
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